Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisense strategies.

Stanley T Crooke1

  • 1Isis Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, CA 92008, USA. scrooke@isisph.com

Current Molecular Medicine
|July 23, 2004
PubMed
Summary
This summary is machine-generated.

Antisense technology uses oligonucleotide analogs to target RNA, offering a new pharmacology for disease treatment. Significant progress has been made, with several drugs in clinical development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing the needs of nano-rare patients: the n-Lorem experience.

Nucleic acids research·2026
Same author

Phosphorothioate antisense oligonucleotide induced innate immune activation is attenuated by tryptophan oxidation products.

Nucleic acids research·2026
Same author

A missense mutation in the SAA1 protein causing hereditary amyloid A amyloidosis.

Kidney international·2026
Same author

Establishing a commercial solution for extremely rare genetic diseases.

Nature biotechnology·2026
Same author

<i>Letter:</i> Correspondence on Damle, S.S., <i>et al.</i> (2025) A Workflow for Transcriptome-Wide Assessment of Antisense Oligonucleotide Selectivity. Nucleic Acid Therapeutics.

Nucleic acid therapeutics·2025
Same author

Splice-modulating antisense oligonucleotides targeting a pathogenic intronic variant in adult polyglucosan body disease correct mis-splicing and restore enzyme activity in patient cells.

Nucleic acids research·2025
Same journal

Corrigendum to: Sortilin as a Culprit in the Atherosclerosis Plaque Progression: Evidence from Clinical and Experimental Studies.

Current molecular medicine·2026
Same journal

Dynamic Expression of Fibroblast Activation Protein (FAP) During Chronic Pancreatitis (CP) Progression in Mice and Evaluation of FAP-targeted Tracers for Early CP Diagnosis.

Current molecular medicine·2026
Same journal

Causal Relationship Between 91 Inflammatory Factors and Gastritis: A Two-Sample Bidirectional Mendelian Randomization Study.

Current molecular medicine·2026
Same journal

Therapeutic Potential of Pistacia Atlantica Gum in Aspirin-Induced Peptic Ulcers: A Dose-Dependent Approach to Mucosal Protection and Hepatorenal Safety.

Current molecular medicine·2026
Same journal

Identification and Characterization of MicroRNAs Associated with Borax-mediated Anti-tumor Activity through High-throughput Technology.

Current molecular medicine·2026
Same journal

Broad-Spectrum Vaccines: Challenges and Opportunities (A Systematic Review).

Current molecular medicine·2026
See all related articles

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Antisense technology utilizes oligonucleotide analogs for targeted RNA binding via Watson-Crick hybridization.
  • This binding can disable target RNA or induce its degradation, and can also modulate RNA splicing.
  • The development of antisense technology represents a novel pharmacological approach, exploring RNA molecules as drug targets.

Purpose of the Study:

  • To review the progress in antisense pharmacology over the past decade.
  • To discuss the limitations and future potential of antisense technology.
  • To summarize advancements in understanding antisense mechanisms, medicinal chemistry, and pharmacological properties.

Main Methods:

  • Review of existing literature on antisense technology.

Related Experiment Videos

  • Analysis of progress in antisense pharmacology, medicinal chemistry, and toxicology.
  • Evaluation of clinical development status and therapeutic applications.

    • Main Results:

    • Substantial progress has been achieved in understanding antisense mechanisms and properties.
    • Antisense technology has proven valuable for gene functionalization and target validation.
    • One antisense drug (Vitravene) is marketed, with approximately 20 others in clinical development.

    Conclusions:

    • Antisense technology has matured significantly, with a growing pipeline of potential therapeutics.
    • Antisense drugs show promise for treating a wide range of diseases.
    • Continued research and development are expected to overcome existing limitations and expand applications.